# Ranolazine Loading to Prevent PCI-induced Myocardial Injury

Study · id `cardio:ct-nct01491061` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01491061](<https://clinicaltrials.gov/study/NCT01491061>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01491061

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01491061. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01491061, source copy `cardio:ctgov-nct01491061-2013-03-07`, retrieved 2026-10-26)
- Start date: 2014-01 (registry gives no type) (ClinicalTrials.gov record NCT01491061, source copy `cardio:ctgov-nct01491061-2013-03-07`, retrieved 2026-10-26)
- Primary completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01491061, source copy `cardio:ctgov-nct01491061-2013-03-07`, retrieved 2026-10-26)
- Completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT01491061, source copy `cardio:ctgov-nct01491061-2013-03-07`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT01491061, source copy `cardio:ctgov-nct01491061-2013-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01491061-2013-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ranolazine Loading to Prevent PCI-induced Myocardial Injury
- Acronym: TWILIGHT
- Condition: Coronary Artery Disease
- Intervention (Drug): Ranolazine
- Intervention (Drug): Placebo
- Lead sponsor: University of Roma La Sapienza
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: University of Roma La Sapienza (`cardio:org-university-of-roma-la-sapienza`)

## Provenance

Content hash: 244bf238e7a8282f5ef35845bb0a7fb6df8a8396e4858b51e9ea9e6b2a3a9ae0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
